News summarySeeking AlphaNov 13, 2026, 02:49 AM
Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M
Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M(摘要待生成)